1
|
Cazals N, Le Hingrat Q, Abraham B, Da Silva P, Guindre L, Goffart S, Damond F, Visseaux B, Charpentier C, Ranger-Rogez S, Descamps D. HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man. Open Forum Infect Dis 2018; 5:ofy223. [PMID: 30310823 PMCID: PMC6174253 DOI: 10.1093/ofid/ofy223] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Accepted: 09/10/2018] [Indexed: 11/20/2022] Open
Abstract
More than 1 million individuals, mainly in West Africa, are thought to be infected with HIV-2. Acute HIV-2 infection is rarely observed, only 2 primary infections have been described to date. We report a detailed case of HIV-2 primary infection in a 69-year-old French bisexual Caucasian man, thereby providing valuable insights into HIV-2 early infection.
Collapse
Affiliation(s)
- Nicolas Cazals
- Service de Médecine Interne, Maladies Infectieuses et Tropicales, Centre Hospitalier de Brive-la-Gaillarde, Brive-la-Gaillarde, France
| | - Quentin Le Hingrat
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
| | - Bruno Abraham
- Service de Médecine Interne, Maladies Infectieuses et Tropicales, Centre Hospitalier de Brive-la-Gaillarde, Brive-la-Gaillarde, France
| | - Patricia Da Silva
- Service de Médecine Interne, Maladies Infectieuses et Tropicales, Centre Hospitalier de Brive-la-Gaillarde, Brive-la-Gaillarde, France
| | - Laure Guindre
- Laboratoire de Microbiologie, Centre Hospitalier de Brive-la-Gaillarde, Brive-la-Gaillarde, France
| | - Sylvie Goffart
- Laboratoire de Microbiologie, Centre Hospitalier de Brive-la-Gaillarde, Brive-la-Gaillarde, France
| | - Florence Damond
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
| | - Benoît Visseaux
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
| | - Charlotte Charpentier
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
| | - Sylvie Ranger-Rogez
- Laboratoire de Virologie, Centre Hospitalier Universitaire de Limoges, Limoges, France
| | - Diane Descamps
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
| |
Collapse
|
2
|
Leow CH, Fischer K, Leow CY, Cheng Q, Chuah C, McCarthy J. Single Domain Antibodies as New Biomarker Detectors. Diagnostics (Basel) 2017; 7:diagnostics7040052. [PMID: 29039819 PMCID: PMC5745390 DOI: 10.3390/diagnostics7040052] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 09/07/2017] [Accepted: 09/08/2017] [Indexed: 01/02/2023] Open
Abstract
Biomarkers are defined as indicators of biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. Biomarkers have been widely used for early detection, prediction of response after treatment, and for monitoring the progression of diseases. Antibodies represent promising tools for recognition of biomarkers, and are widely deployed as analytical tools in clinical settings. For immunodiagnostics, antibodies are now exploited as binders for antigens of interest across a range of platforms. More recently, the discovery of antibody surface display and combinatorial chemistry techniques has allowed the exploration of new binders from a range of animals, for instance variable domains of new antigen receptors (VNAR) from shark and variable heavy chain domains (VHH) or nanobodies from camelids. These single domain antibodies (sdAbs) have some advantages over conventional murine immunoglobulin owing to the lack of a light chain, making them the smallest natural biomarker binders thus far identified. In this review, we will discuss several biomarkers used as a means to validate diseases progress. The potential functionality of modern singe domain antigen binders derived from phylogenetically early animals as new biomarker detectors for current diagnostic and research platforms development will be described.
Collapse
Affiliation(s)
- Chiuan Herng Leow
- Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, Malaysia.
| | - Katja Fischer
- Bacterial Pathogenesis and Scabies Laboratory, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia.
| | - Chiuan Yee Leow
- Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Kelantan 16150, Malaysia.
| | - Qin Cheng
- Department of Drug Resistance and Diagnostics, Australian Army Malaria Institute, Brisbane 4051, Australia.
| | - Candy Chuah
- Department of Medical Microbiology & Parasitology, School of Medical Sciences, Universiti Sains Malaysia, Kelantan 16150, Malaysia.
| | - James McCarthy
- Clinical Tropical Medicine Laboratory, QIMR Berghofer Medical Research Institute, Brisbane 4029, Australia.
| |
Collapse
|
3
|
Vetter BN, Orlowski V, Fransen K, Niederhauser C, Aubert V, Brandenberger M, Ciardo D, Dollenmaier G, Klimkait T, Regenass S, Schmid P, Schottstedt V, Suter-Riniker F, Yerly S, Shah C, Böni J, Schüpbach J. Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests. PLoS One 2014; 9:e111552. [PMID: 25343245 PMCID: PMC4208835 DOI: 10.1371/journal.pone.0111552] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Accepted: 09/28/2014] [Indexed: 02/07/2023] Open
Abstract
Background Detection of HIV-1 p24 antigen permits early identification of primary HIV infection and timely intervention to limit further spread of the infection. Principally, HIV screening should equally detect all viral variants, but reagents for a standardised test evaluation are limited. Therefore, we aimed to create an inexhaustible panel of diverse HIV-1 p24 antigens. Methods We generated a panel of 43 recombinantly expressed virus-like particles (VLPs), containing the structural Gag proteins of HIV-1 subtypes A-H and circulating recombinant forms (CRF) CRF01_AE, CRF02_AG, CRF12_BF, CRF20_BG and group O. Eleven 4th generation antigen/antibody tests and five antigen-only tests were evaluated for their ability to detect VLPs diluted in human plasma to p24 concentrations equivalent to 50, 10 and 2 IU/ml of the WHO p24 standard. Three tests were also evaluated for their ability to detect p24 after heat-denaturation for immune-complex disruption, a pre-requisite for ultrasensitive p24 detection. Results Our VLP panel exhibited an average intra-clade p24 diversity of 6.7%. Among the 4th generation tests, the Abbott Architect and Siemens Enzygnost Integral 4 had the highest sensitivity of 97.7% and 93%, respectively. Alere Determine Combo and BioRad Access were least sensitive with 10.1% and 40.3%, respectively. Antigen-only tests were slightly more sensitive than combination tests. Almost all tests detected the WHO HIV-1 p24 standard at a concentration of 2 IU/ml, but their ability to detect this input for different subtypes varied greatly. Heat-treatment lowered overall detectability of HIV-1 p24 in two of the three tests, but only few VLPs had a more than 3-fold loss in p24 detection. Conclusions The HIV-1 Gag subtype panel has a broad diversity and proved useful for a standardised evaluation of the detection limit and breadth of subtype detection of p24 antigen-detecting tests. Several tests exhibited problems, particularly with non-B subtypes.
Collapse
Affiliation(s)
- Beatrice N. Vetter
- Swiss National Center for Retroviruses (SNCR), Institute of Medical Virology, University of Zürich, Zürich, Switzerland
- * E-mail:
| | - Vanessa Orlowski
- Swiss National Center for Retroviruses (SNCR), Institute of Medical Virology, University of Zürich, Zürich, Switzerland
| | - Katrien Fransen
- Institute of Tropical Medicine (ITG), Clinical Science, Antwerp, Belgium
| | | | - Vincent Aubert
- University Hospital, Service of Immunology and Allergy, CHUV, Lausanne, Switzerland
| | | | | | | | - Thomas Klimkait
- Department Biomedicine, Haus Petersplatz, University of Basel, Basel, Switzerland
| | | | - Patrick Schmid
- Department of Infectious Diseases, Cantonal Hospital St. Gallen (KSSG), St. Gallen, Switzerland
| | | | | | - Sabine Yerly
- University Hospitals (HUG), Laboratory of Virology, Genève, Switzerland
| | - Cyril Shah
- Swiss National Center for Retroviruses (SNCR), Institute of Medical Virology, University of Zürich, Zürich, Switzerland
| | - Jürg Böni
- Swiss National Center for Retroviruses (SNCR), Institute of Medical Virology, University of Zürich, Zürich, Switzerland
| | - Jörg Schüpbach
- Swiss National Center for Retroviruses (SNCR), Institute of Medical Virology, University of Zürich, Zürich, Switzerland
| |
Collapse
|
4
|
Abstract
Due to technical improvements and new developments of immunological assays, the reliability of serological laboratory diagnosis of HIV infection has improved considerably and the residual risk, due to the diagnostic window for transfusion-transmitted HIV, has been reduced significantly. Through the addition of nucleic acid amplification tests (NAT) to blood donor screening, the residual risk can de further decreased by up to 50%, depending on the sensitivity of the NAT protocol and whether individual or pooled blood donations are screened. In-house and commercially available NAT have been implemented in blood banks as HIV only or multiplexed HIV and hepatitis B or C virus assays. As an alternative to separate antigen and antibody screening, combined fourth-generation assays have been developed in 1997, and have achieved a high degree of sensitivity and specificity. Thus, they can replace stand-alone antigen and third-generation antibody assays. While they are used in the routine diagnostics of HIV infection in many countries throughout the world, they probably represent no alternative for NAT in blood-donor screening in industrialized countries. In the next few years, technical improvements will further simplify NAT screening. While there is still some potential to improve the detection threshold of NAT, the sensitivity of the antigen module of fourth-generation assays (a lowest concentration of 3-5 pg of p24 antigen) is probably very close to its technical limit.
Collapse
Affiliation(s)
- Bernard Weber
- Laboratoires Réunis, ZI Langwies, L-6131 Junglinster, Luxembourg.
| |
Collapse
|
5
|
Yeom JS, Jun G, Chang Y, Sohn MJ, Yoo S, Kim E, Ryu SH, Kang HJ, Kim YA, Ahn SY, Cha JE, Youn ST, Park JW. Evaluation of a new fourth generation enzyme-linked immunosorbent assay, the LG HIV Ag-Ab Plus, with a combined HIV p24 antigen and anti-HIV-1/2/O screening test. J Virol Methods 2006; 137:292-7. [PMID: 16908076 DOI: 10.1016/j.jviromet.2006.07.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2005] [Revised: 07/01/2006] [Accepted: 07/04/2006] [Indexed: 10/24/2022]
Abstract
The LG HIV Ag-Ab Plus, a new fourth generation diagnostic assay for HIV infection, was evaluated in comparison to the Enzygnost HIV Integral, an established fourth generation HIV assay. The LG assay showed 100% sensitivity with 109 samples with anti-HIV-1, anti-HIV-2 or anti-HIV-1 group O reactivity. It also detected correctly all 51 positives on three BBI performance panels, slightly outperforming the Enzygnost HIV Integral, which detected 50. The specificity of the LG HIV Ag-Ab Plus was 99.9% with 999 sera from healthy blood donors, which was slightly inferior to the performance of the Enzygnost HIV Integral, which had 100% specificity. The LG assay showed 100% specificity with 81 specimens with underlying diseases including hepatitis B, demonstrating a low risk of cross-reactivity with other infections. The reduction of the diagnostic window by the LG HIV Ag-Ab Plus, compared to a third generation HIV assay, was 6.3 days. The LG assay also showed sufficiently high intra-person and inter-person reproducibility. The overall performance of this new fourth generation HIV assay was adequate for screening and diagnosis of HIV infection.
Collapse
Affiliation(s)
- Joon-Sup Yeom
- Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Weber B, Gürtler L, Thorstensson R, Michl U, Mühlbacher A, Bürgisser P, Villaescusa R, Eiras A, Gabriel C, Stekel H, Tanprasert S, Oota S, Silvestre MJ, Marques C, Ladeira M, Rabenau H, Berger A, Schmitt U, Melchior W. Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity. J Clin Microbiol 2002; 40:1938-46. [PMID: 12037046 PMCID: PMC130745 DOI: 10.1128/jcm.40.6.1938-1946.2002] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2001] [Revised: 01/05/2002] [Accepted: 02/13/2002] [Indexed: 01/22/2023] Open
Abstract
Fourth-generation assays for the simultaneous detection of human immunodeficiency virus (HIV) antigen and antibody that were available on the international market until now have antigen detection modules with relatively poor sensitivity and produce a higher rate of false-positive results than third-generation enzyme immunoassays (EIAs). The new Cobas Core HIV Combi EIA with an improved sensitivity for HIV p24 antigen was compared to alternative fourth- and third-generation assays, the p24 antigen test, and HIV type 1 (HIV-1) RNA reverse transcriptase PCR (RT-PCR). A total of 94 seroconversion panels (n = 709 sera), samples from the acute phase of infection after seroconversion (n = 32), anti-HIV-1-positive specimens (n = 730) from patients in different stages of the disease, 462 subtyped samples from different geographical locations, anti-HIV-2-positive sera (n = 302), dilutions of cell culture supernatants (n = 62) from cells infected with different HIV-1 subtypes, selected performance panels from Boston Biomedica Inc., 7,579 unselected samples from blood donors, 303 unselected daily routine samples, 997 specimens from hospitalized patients, and potentially interfering samples (n = 1,222) were tested with Cobas Core HIV Combi EIA. The new assay showed a sensitivity comparable to that of the Abbott HIV-1 AG Monoclonal A for early detection of HIV infection in seroconversion panels. The mean time delay of Cobas Core HIV Combi EIA (last negative sample plus 1 day) in comparison to that for HIV-1 RT-PCR for 87 panels tested with both methods was 2.75 days. The diagnostic window was reduced with Cobas Core HIV Combi EIA by between 3.6 and 5.7 days from that for third-generation assays. The specificities of Cobas Core HIV Combi EIA in blood donors were 99.84 and 99.85% (after repeated testing). Overall, 30 repeatedly reactive false-positive results out of 10,031 HIV-negative samples were obtained with Cobas Core HIV Combi EIA. Our results show that a fourth-generation assay with improved specificity such as Cobas Core HIV Combi EIA is suitable for blood donor screening because of its low number of false positives and because it detects HIV p24 antigen with a sensitivity comparable to that of single-antigen assays.
Collapse
Affiliation(s)
- Bernard Weber
- Laboratoires Réunis Kutter-Lieners-Hastert, Junglinster, Luxembourg.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Makuwa M, Souquière S, Niangui MT, Rouquet P, Apetrei C, Roques P, Simon F. Reliability of rapid diagnostic tests for HIV variant infection. J Virol Methods 2002; 103:183-90. [PMID: 12008012 DOI: 10.1016/s0166-0934(02)00026-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The sensitivity of one ELISA method, six HIV-1/HIV-2 rapid screening tests, and one confirmatory test was evaluated in comparison with a third-generation EIA method (taken as the 'gold standard') and Western blot on well-characterized panels of sera. HIV diversity was represented by 50 HIV-1 group M subtype A to H, nine HIV-1 group O, 12 HIV-2, two HIV1+2 positive and six indeterminate Western blot profiles. Sensitivity during HIV-1 seroconversion was studied on 39 serial samples collected from six patients during early primary infection. Serial samples obtained from two primates during experimental primary SIV infection were used to mimic HIV-2 seroconversion samples. The sensitivity ranged from 100 to 94.6% according to the test. During seroconversion, rapid tests became positive 2-8 days later than the third-generation EIA. This reveals a major limitation of rapid tests, which are being recommended for use in developing countries. The lack of sensitivity seen during early HIV-1 seroconversion and/or limited specificity in some of the evaluated tests present serious limitations to their use in countries with high HIV incidence and variability. It is suggested that, as soon as possible, less sensitive rapid tests for blood bank screening should be abandoned in favor of highly sensitive rapid tests and/or more robust, more sensitive and cheaper ELISAs. These results stress the need for better screening tools and specific local evaluations.
Collapse
Affiliation(s)
- Maria Makuwa
- Centre International de Recherches Médicales, Franceville, Gabon.
| | | | | | | | | | | | | |
Collapse
|
8
|
Thorstensson R, Andersson S, Lindbäck S, Dias F, Mhalu F, Gaines H, Biberfeld G. Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel. J Virol Methods 1998; 70:139-51. [PMID: 9562408 DOI: 10.1016/s0166-0934(97)00176-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The performance of 14 commercially available HIV-1/2 antibody assays were compared using well-characterized serum panels containing in total 1500 1800 sera. The panels included consecutive HIV-negative blood donor sera from Sweden, unselected blood donor and patient sera from Tanzania and unselected sera from outpatient clinics in Guinea-Bissau. Furthermore selected HIV-1 antibody positive sera from Sweden and Tanzania and HIV-2 antibody positive sera from Guinea-Bissau were included in the panels. The HIV-1 antibody positive sera were from individuals at various stages of HIV infection, from primary infection, to asymptomatic phase and late stage disease. 12 of the 14 assays identified correctly all HIV-1 and HIV-2 antibody positive sera. One Tanzanian HIV-1 antibody positive sample with complete banding pattern on Western blot was not detected by two of the ELISAs employing synthetic peptides. There were small differences in sensitivity between the assays when used for analysis of seroconversion panels. The most sensitive assay, Abbott IMx HIV-1/HIV-2 III Plus detected antibodies in all nine samples collected from four individuals during the first week after onset of symptoms of primary HIV-1 infection. Most of the assays became reactive during the second week after onset of symptoms and the least sensitive assays were reactive from the third week. The assays showed a high specificity ranging from 99.2 to 100% when used for analysis of Swedish blood donor sera, while most of the assays showed a significantly lower specificity, 91.9-99.6%, when used for testing African specimens.
Collapse
Affiliation(s)
- R Thorstensson
- Swedish Institute for Infectious Disease Control and Karolinska Institute, Stockholm.
| | | | | | | | | | | | | |
Collapse
|